RTTNews | Jul 6, 2021 06:50AM EDT

06:49 Tuesday, July 6, 2021 (RTTNews.com) - CytoDyn Inc. (CYDY) on Tuesday said its lead drug candiate, leronlimab, has been granted patent for methods of treating coronavirus infection by the U.S. Patent and Trademark Office (USPTO).

The patent, which is awarded for methods of treating hyperinflammation, a common complication of COVID-19, is expected to be valid at least through June 15, 2040.

The FDA had granted fast track designation to leronlimab for the potential treatments for Human Immunodeficiency Virus (HIV) and metastatic cancer.

"Our steady push to reach the finish line includes our BLA for HIV, which we believe to be back on track, pursuit of Breakthrough Therapy designation based on significant positive results from our COVID-19 long-haulers trial (CD15), initiation of two COVID-19 trials in Brazil in the near future, reaching the targeted enrollment of 60 patients in our Phase 2 NASH trial ahead of the previously scheduled timeline with trial results expected before yearend, and many more developments anticipated later this year," said Nader Pourhassan, CytoDyn's President and Chief Executive Officer.

Read the original article on RTTNews ( https://www.rttnews.com/3207095/cytodyn-gets-patent-for-methods-of-treating-coronavirus.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved